| Rose Mountain Care Center | |
| Route 1 & 18, New Brunswick, New Jersey 08901 | |
| (732) 828-2400 | |
| Name | Rose Mountain Care Center |
|---|---|
| Location | Route 1 & 18, New Brunswick, New Jersey |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 112 |
| Occupancy Rate | 65.8% |
| Medicare ID (CCN) | 315384 |
| Legal Business Name | Rose Mountain Care Center, Inc. |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1639269129 |
| Organization Name | ROSE MOUNTAIN CARE CENTER, INC. |
| Address | Route 1 And 18, New Brunswick, NJ 08901 |
| Phone Number | 732-828-2400 |
News Archive
On February, 5, orthopaedic surgeon Thomas Ferro, MD, successfully performed a total knee replacement procedure using Insurgical single-use orthopaedic power tools. This operation marked the first time FDA cleared single-use, cordless, handheld power tools were used in an orthopaedic operation in the United States. Specialty surgical power tools used to cut and shape bone are required in over 1.5 million orthopaedic procedures annually in the United States.
PriceWaterhouseCoopers is estimating that employer health costs will rise 9 percent in 2011, slightly less than they rose in 2010, Reuters reports. "The PriceWaterhouseCoopers team questioned 700 companies in 30 industries for the report. About 60 percent of Americans under the age of 65 get health insurance through an employer. Health benefits are often a major part of any employee compensation package. Most employers, 63 percent, offer a [managed-care] preferred provider organization or PPO, the survey found. And many have raised the deductible, with 43 percent having a deductible of $400 or more, compared to 25 percent in 2009."
Given her relatively young age, Dr. Rae Lyn Burke didn't think much about her family history of Alzheimer's disease - a grandmother and an aunt had suffered from it, but they were much older. Ironically, Burke was just in her late 50s when she started having her own symptoms of early onset Alzheimer's. Even more ironic is that Burke had been one of the key developers of the Alzheimer's drug bapineuzumab, which she now takes herself to reduce the progression of the disease in her own brain.
Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, has published research in Nature Chemical Biology demonstrating the first-ever selective irreversible inhibition of a viral protease using a targeted covalent drug.
› Verified 6 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
On February, 5, orthopaedic surgeon Thomas Ferro, MD, successfully performed a total knee replacement procedure using Insurgical single-use orthopaedic power tools. This operation marked the first time FDA cleared single-use, cordless, handheld power tools were used in an orthopaedic operation in the United States. Specialty surgical power tools used to cut and shape bone are required in over 1.5 million orthopaedic procedures annually in the United States.
PriceWaterhouseCoopers is estimating that employer health costs will rise 9 percent in 2011, slightly less than they rose in 2010, Reuters reports. "The PriceWaterhouseCoopers team questioned 700 companies in 30 industries for the report. About 60 percent of Americans under the age of 65 get health insurance through an employer. Health benefits are often a major part of any employee compensation package. Most employers, 63 percent, offer a [managed-care] preferred provider organization or PPO, the survey found. And many have raised the deductible, with 43 percent having a deductible of $400 or more, compared to 25 percent in 2009."
Given her relatively young age, Dr. Rae Lyn Burke didn't think much about her family history of Alzheimer's disease - a grandmother and an aunt had suffered from it, but they were much older. Ironically, Burke was just in her late 50s when she started having her own symptoms of early onset Alzheimer's. Even more ironic is that Burke had been one of the key developers of the Alzheimer's drug bapineuzumab, which she now takes herself to reduce the progression of the disease in her own brain.
Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, has published research in Nature Chemical Biology demonstrating the first-ever selective irreversible inhibition of a viral protease using a targeted covalent drug.
› Verified 6 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 20.33 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 14.46 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 5.88 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.9 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 1.21 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 9.96 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 2.16 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 86.33 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 8.44 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 53.7 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 16 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 8.46 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 8.62 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 96.61 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 89.76 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 59.06 | 82.93 |
News Archive
On February, 5, orthopaedic surgeon Thomas Ferro, MD, successfully performed a total knee replacement procedure using Insurgical single-use orthopaedic power tools. This operation marked the first time FDA cleared single-use, cordless, handheld power tools were used in an orthopaedic operation in the United States. Specialty surgical power tools used to cut and shape bone are required in over 1.5 million orthopaedic procedures annually in the United States.
PriceWaterhouseCoopers is estimating that employer health costs will rise 9 percent in 2011, slightly less than they rose in 2010, Reuters reports. "The PriceWaterhouseCoopers team questioned 700 companies in 30 industries for the report. About 60 percent of Americans under the age of 65 get health insurance through an employer. Health benefits are often a major part of any employee compensation package. Most employers, 63 percent, offer a [managed-care] preferred provider organization or PPO, the survey found. And many have raised the deductible, with 43 percent having a deductible of $400 or more, compared to 25 percent in 2009."
Given her relatively young age, Dr. Rae Lyn Burke didn't think much about her family history of Alzheimer's disease - a grandmother and an aunt had suffered from it, but they were much older. Ironically, Burke was just in her late 50s when she started having her own symptoms of early onset Alzheimer's. Even more ironic is that Burke had been one of the key developers of the Alzheimer's drug bapineuzumab, which she now takes herself to reduce the progression of the disease in her own brain.
Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, has published research in Nature Chemical Biology demonstrating the first-ever selective irreversible inhibition of a viral protease using a targeted covalent drug.
› Verified 6 days ago
Rose Mountain Care Center Location: Route 1 & 18, New Brunswick, New Jersey 08901 Phone: (732) 828-2400 |